bioAffinity Technologies Analyst Price Targets - Benzinga

bioAffinity Technologies Inc

BIAFNASDAQ

Trade with Public

Trade with Public

$3.03

-0.11-3.5%

Últ. Act.: Oct 29, 5:54 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Informe de acciones

bioAffinity Technologies Analyst Price Targets - Benzinga

bioAffinity Technologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for bioAffinity Technologies (BIAF).

Price Target Range —

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 1, 2025	Maxim Group	Anthony Vendetti	Downgrade	Buy→Hold	—
Jul 23, 2024	Maxim Group	Anthony Vendetti	Initiate	Buy	$2700

Analyst Ratings News

PRO
Maxim Group Downgrades bioAffinity Technologies to Hold

Maxim Group analyst Anthony Vendetti downgrades bioAffinity Technologies (NASDAQ:BIAF) from Buy to Hold.

Benzinga Newsdesk

US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert

U.S. stock futures were swinging between gains and losses on Tuesday after a mixed session on Monday. Futures of major benchmark indices were mixed in premarket trading. President Donald Trump‘s “Liberation Day”, the term he’s used for April 2nd, the day of incoming reciprocal tariffs, preceded a drop in stock prices.

Rishabh Mishra

PRO
Maxim Group Initiates Coverage On bioAffinity Technologies with Buy Rating, Announces Price Target of $6

Maxim Group analyst Anthony Vendetti initiates coverage on bioAffinity Technologies (NASDAQ:BIAF) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk